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Visceral fat mass: is it the link between uric
acid and diabetes risk?
Neda Seyed-Sadjadi1, Jade Berg2, Ayse A. Bilgin3 and Ross Grant1,2,4*
Abstract
Background: Uric acid (UA) has been suggested as a novel risk factor for diabetes. However, its definite role in this
prevalent disease is still the subject of much discussion because it is always accompanied with other major risk
factors such as obesity and high visceral adiposity. In order to clarify the role of UA in diabetes, this study aimed to
investigate the associations between plasma UA and fasting plasma glucose, HbA1c, lipid profile and inflammatory
markers after accounting for the contribution of other diabetes risk factors such as BMI and VAT fat mass.
Methods: In the present cross-sectional study, 100 non-diabetic middle-aged males (n = 48) and females (n = 52)
were recruited. Central fat distribution measures including android to gynoid fat ratio, VAT and subcutaneous adipose
tissue (SAT) fat mass were determined using dual-energy X-ray absorptiometry (DXA). Biochemical analysis was done
using methods well established for clinical and research laboratories. Multiple linear regression analysis was performed
to analyse the association between plasma UA and the biochemical and central fat distribution measures.
Results: UA was positivly associated with body mass index (BMI) (r (98) = 0.42, P ≤ 0.001), android to gynoid fat ratio
(r (98) = 0.62, P ≤ 0.001) and VAT fat mass (r (96) = 0.55, P ≤ 0.001). UA was also positively associated with plasma
glucose (r (98) = 0.33, P ≤ 0.001), hemoglobin A1c (r (93) = 0.25, P = 0.014), plasma triglyceride (rs (95) = 0.40, P ≤ 0.001),
HDL cholesterol (r (98) = − 0.61, P ≤ 0.001) and CRP (rs (98) = 0.23, P = 0.026). However, these associations were no
longer significant after accounting for BMI or/and VAT fat mass. No significant association was observed between UA
and SAT fat mass (r (97) = 0.02, P ≥ 0.05), Total cholesterol (r (98) = 0.03, P ≥ 0.05), LDL cholesterol (r (98) = 0.13, P ≥ 0.
05), TNF-α (r (97) = 0.12, P ≥ 0.05) and IL-6 (r (96) = −0.02, P ≥ 0.05).
Conclusion: Results from this study suggest, for the first time, that the association between plasma UA and glucose in
a non-diabetic population is not direct but rather dependent on VAT fat mass.
Keywords: Diabetes, Uric acid, Glucose, HbA1c, Triglyceride, Inflammation, BMI, Android fat, Gynoid fat, Visceral fat mass
Background
The predicted increase in diabetes prevalence from 366
million in 2011 to an estimated 552 million by 2030
highlights the critical need for preventive strategies to
this ubiquitous degenerative disease [1]. Identifying the
risk factors for developing diabetes is crucial for preven-
tion. In this context, uric acid (UA), the end product of
purine metabolism, has been proposed as a novel risk
factor for diabetes [2–4]. A meta-analysis of cohort
studies reported an overall 17% increase in diabetes risk
with every 0.059 mmol/L serum UA elevation [4].
However, recognition of high serum UA as a risk fac-
tor for diabetes has been a matter of debate for some
time with consensus on the final mechanism still unre-
solved. Even though some studies have shown a positive
correlation between serum UA and levels of fasting
plasma glucose (FPG) [5, 6], glycated hemoglobin A1c
(HbA1c) [6], triglyceride (TG) [5, 7, 8], and inflamma-
tory markers [9] and inverse correlations with high dens-
ity lipoprotein cholesterol (HDL-C) levels [7, 8], other
studies have actually observed an inverse association be-
tween serum UA and diabetes [10, 11]. More import-
antly, whether UA exerts its effect independent of other
established diabetes risk factors is still not known.
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Although many previous studies have accounted for a
substantial range of potential metabolic confounders in
their design [12, 13], there is still one major risk factor
with strong correlation with UA that has not been
accounted for.
UA levels have been shown to be strongly correlated
with body mass index (BMI) (14), android to gynoid fat
ratio (15) and more specifically, visceral adipose tissue
(VAT), a component of android fat mass (14, 15). There
is plenty of evidence suggesting that obesity (BMI ≥ 25)
and high android to gynoid fat ratio are important fea-
tures of insulin resistance and diabetes [14–16]. In par-
ticular, excess accumulation of (VAT) fat mass has been
reported to be associated with insulin resistance by re-
lease of free fatty acids, hormones, and inflammatory
proteins and chemokines [17]. There is also evidence
that subcutaneous adipose tissue (SAT), another compo-
nent of android fat, impacts the development of obesity
related insulin resistance by releasing fatty acids [18].
The intercorrelations among obesity, VAT fat mass,
serum UA and diabetes make it difficult to determine
whether or not an elevated serum UA level is an inde-
pendent causative risk factor or rather a dependent
marker subordinate to the pathological changes occur-
ring in diabetes. A better understanding of the relation-
ships between plasma UA levels and these risk factors of
diabetes is necessary to clarify the definite role of UA in
diabetes development. Even though the role of BMI and
waist circumference has been accounted for in many
studies [12, 13]; the specific role of VAT fat mass has
not yet been considered. Furthermore, the relationship
between diabetes risk factors and serum UA levels in a
non-diabetic population is still less known and needs
further investigation. In this study, we investigated
whether plasma UA concentration was associated with
diabetes risk factors such as FPG, HbA1c, lipid profile
and inflammatory markers in middle-aged non-diabetics
independent of BMI and VAT fat mass. To the best of
our knowledge, this is the first examination of non-
diabetic males and females for these associations taking
in to account VAT fat mass.
Methods
Participants
In this cross-sectional study male (n = 48) and female
(n = 52) participants aged between 40 and 75 years were
recruited at Sydney Adventist hospital and the university
of New South Wales campuses. Participants were non-
diabetics and considered in general good health. Blood
collection and body scanning for central fat distribution
analysis were performed on the same day in a fasted
state (about 12 h) after obtaining written informed con-
sent. Ethical approval of the study was obtained from
the Adventist HealthCare Limited Human Research
Ethics Committee, Sydney Adventist Hospital, Australia
(HREC number: 2013–022).
Biochemical analysis
The measurements of plasma UA, FPG, HbA1c, total
cholesterol (TC), Low density lipoprotein cholesterol
(LDL-C), HDL-C and TG and C-reactive protein
(CRP) were performed by the Sydney Adventist
Hospital pathology laboratory using methods well
established for clinical laboratories. Briefly, fasting
plasma UA, FPG, TG, TC, and HDL-C levels were de-
termined by the enzymatic method on a Roche/Hita-
chi cobas c system. LDL-C levels were calculated by
the Friedewald eq. [19]. Plasma HbA1c concentration
was measured by ion-exchange high-performance
liquid chromatography (HPLC) on the D-100
hemoglobin testing system (Bio-Rad Laboratories,
Hercules, CA, USA). Plasma CRP was measured by
Immunoturbidimetric assay on a Roche/Hitachi cobas
c system. Plasma tumor necrosis factor- α (TNF-α)
and interleukin-6 (IL-6) levels were quantitated using
the MILLIPLEX® MAP Human High Sensitivity T Cell
Magnetic Bead Panel immunoassay (Merck KGaA,
Darmstadt, Germany). Estimated Glomerular filtration
rate (eGFR) was calculated using the simplified
Modification of Diet in Renal Disease study equation:
GFR (ml/min/1.73m2) = 186 × (serum creatinine level
[mg/dl])-1.154 × (age)-0.203× [0.742, if female] × [1.212, if
black] [20, 21].
Central fat distribution analysis
Dual-energy X-ray absorptiometry (DXA) method was
used to measure central fat distribution by a Lunar
iDXA (GE Healthcare, Madison, WI, USA) with auto-
matic total body scan mode and enCORE software (ver-
sion 16, GE Healthcare, Madison, WI, USA). All
participants were scanned by trained operators accord-
ing to the standard methods. Quality control scans were
obtained daily using the manufacturer supplied calibra-
tion phantom. All metal items were removed from the
participant before scanning. The participants were asked
to change into a standard cloth gown and were correctly
centred on the scanning table in a supine position with
arms at sides slightly separated from the trunk and the
palms facing the thighs.
The regions of interest (ROIs) for regional body com-
position were automatically drawn by the software
according to anatomical landmarks and then double-
checked with a trained operator for obtaining the best
position. Two ROIs were considered in this study: an-
droid and gynoid ROIs. Android region (roughly 10 cm
in height) was defined as a portion of the abdomen in-
cluded between pelvis cut line (the line joining the two
superior iliac crests) and the 20% of the distance
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between pelvis cut line and neck cut line. Gynoid re-
gion (two times the android region) was defined as a
portion of legs beginning at a distance of 1.5 times
android ROI height below pelvis cut line and directed
caudally up to a distance double that of the height of
the Android ROI [22].
Central fat distribution pattern was assessed by the an-
droid to gynoid fat ratio that is the ratio of android fat
(kg) divided by gynoid fat (kg). VAT fat mass was com-
puted automatically for the android ROI by CoreScan al-
gorithm, a new software option in enCORE for the
estimation of visceral fat mass within the android region
[23]. In the android ROI, SAT was calculated manually
by subtracting VAT from total android fat mass.
Anthropometric measures were obtained using a stan-
dardized protocol. Weight (kg) and height (cm) were
measured to the nearest 0.5 kg and 0.1 cm, with partici-
pants wearing a cloth gown and without shoes. BMI was
calculated as weight in kilograms divided by the square
of the height in meters.
Statistical analysis
Statistical analysis was performed using SPSS version 23
for Windows. Values are presented as means ± standard
deviations. The Kolmogorov-Smirnov and Shapiro-Wilk
tests were used to test the normality of the variables. After
checking graphical displays and applying appropriate stat-
istical rules, outliers were removed for UA (*2), TG (*3),
VAT (*3) and SAT fat mass (*1), CRP (*3), IL-6 (*1) and
TNF-α (*1). Correlations between variables were deter-
mined using Pearson’s (r (n)) or Spearman’s (rs (n)) correl-
ation coefficients, as appropriate. The Student’s t-test or
Mann-Whitney U-test were used, as appropriate, to deter-
mine differences in the means of continuous variables.
Finally, multiple linear regression analysis was per-
formed to determine the association between the plasma
UA and FPG, HbA1c, TG, HDL-C, CRP, BMI, and abdom-
inal adiposity measures including android to gynoid fat ra-
tio and the VAT fat mass, after adjustment for age, gender,
eGFR, BMI and/or VAT fat mass. The Levene’s Test of
Equality was applied to check homogeneity of variances
between groups. If the variances of the groups were either
not homogenous and/or normality tests for the variables/
multiple linear regression models were significant then
further examination with graphical displays was per-
formed and where needed base-10 log-transformed
means, square roots or reciprocals were used or the asso-
ciation was analysed separately for each group. P values
less than 0.05 were considered statistically significant.
Results
Among a total of 100 subjects, 48 were males and 52
were females. Clinical characteristics of the study partici-
pants are shown in Table 1. The mean age was
56.0 ± 8.8 years. The mean FPG and HbA1c levels were
5.1 ± 0.6 mmol/L and 34.6 ± 3.5 mmol/mol, respectively.
There were no significant differences between genders
for either FPG or HbA1c levels. The mean plasma UA
levels were 0.3 ± 0.07 mmol/L. Average UA levels were
significantly higher for males than females. There were
no significant differences between genders for plasma
levels of TG, LDL-C, TC, eGFR, and inflammatory
markers (i.e. CRP, TNF- α, and IL-6). However, as ex-
pected, HDL-C levels were significantly higher in fe-
males than males. The mean values for BMI, android to
gynoid fat ratio, VAT and SAT fat mass were
26.2 ± 4.6 kg/m2, 1.1 ± 0.3, 953.1 ± 798.3 g and
1314.4 ± 673.8 g, respectively. The mean BMI was not
statistically significant between genders. However, there
were statistically significant differences between gen-
ders for android to gynoid fat ratio, VAT and SAT fat
mass values. Android to gynoid fat ratio and VAT fat
mass were significantly higher in males than females,
while SAT fat mass was significantly higher in females
than in males.
Associations between BMI, and central fat distribution
parameters (android to gynoid fat ratio, VAT and SAT fat
mass) and plasma TG and FPG
As expected, a statistically positive association was ob-
served between FPG and BMI (r (100) = 0.31, P ≤ 0.01).
This association remained statistically significant after
controlling for age, gender and eGFR (t (94) = 2.92,
P = 0.004, R2 = 0.14). FPG was also significantly associ-
ated with android to gynoid fat ratio (r(100) = 0.384,
P ≤ 0.001). This association remained statistically signifi-
cant after controlling for age, gender and eGFR (t
(94) = 3.73, P ≤ 0.001, R2 = 0.18).
A statistically significant association was also observed
between FPG and VAT fat mass (r (97) = 0.32,
P ≤ 0.001) that remained statistically significant after
controlling for age, gender and eGFR (t (91) = 2.84,
P ≤ 0.01, R2 = 0.13). No association was observed be-
tween FPG and SAT fat mass (r (99) = 0.107, P ≥ 0.05).
Also, there was a statistically significant association be-
tween FPG and TG (r (97) = 0.46, P ≤ 0.001). Since the
residuals for the linear regression model were not nor-
mally distributed when gender was in the equation, the
association between plasma TG and FPG was analysed
separately for each gender. The results showed that after
controlling for age, eGFR and BMI there was a statisti-
cally significant association between FPG and plasma
TG in both males (t (39) = 2.18, P = 0.035, R2 = 0.26)
and females (t (47) = 3.58, P ≤ 0.001, R2 = 0.24).
Associations between plasma UA, FPG and plasma HbA1c
There was a statistically significant positive association
between plasma UA and FPG (r (98) = 0.33, P ≤ 0.001)
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(Fig. 1). This association remained statistically significant
after adjustment for age, gender and eGFR (t (92) = 2.67,
P ≤ 0.01, R2 = 0.14). However, it did not remain signifi-
cant after further adjustment for BMI (t (91) = 1.76,
P ≥ 0.05, R2 = 0.15) or VAT fat mass (t (89) = 1.64,
P ≥ 0.05, R2 = 0.15).
A statistically significant positive association was
observed between plasma UA and plasma HbA1c (r
(93) = 0.25, P = 0.014) (Fig. 1). This association remained
statistically significant after adjustment for age, gender
and eGFR (t (87) = 2.12, P = 0.036, R2 = 0.08). However,
as with FPG, the association did not remain significant
after further adjustment for BMI (t (86) = 1.37, P ≥ 0.05,
R2 = 0.08) or VAT fat mass (t (84) = 1.09, P ≥ 0.05,
R2 = 0.08).
Associations between plasma UA, BMI and central fat
distribution parameters (android to gynoid fat ratio, VAT
and SAT fat mass)
A statistically significant positive association was ob-
served between plasma UA and BMI (r (98) = 0.42,
P ≤ 0.001) (Fig. 2). This association remained statistically
significant after controlling for age, gender and eGFR (t
(92) = 4.96, P ≤ 0.001, R2 = 0.44). However, it did not
remain significant after adding and adjusting for VAT fat
mass (t (89) = 1.26, P ≥ 0.05, R2 = 0.44). This model was
able to account for 44% of variability in mean plasma
UA levels.
There was a statistically significant positive association
between plasma UA and android to gynoid fat ratio (r
(98) = 0.62, P ≤ 0.001). This association remained
statistically significant after controlling for age, gender,
eGFR and BMI (t (91) = 2.44, P = 0.017, R2 = 0.47), but
no longer remained significant after adjusting for VAT
fat mass (t (89) = 1.48, P ≥ 0.05, R2 = 0.45).
A positive association between plasma UA and VAT
fat mass was also observed (r (96) = 0.55, P ≤ 0.001)
(Fig. 2). This association remained statistically significant
after controlling for age, gender and eGFR (t (90) = 4.96,
P ≤ 0.001, R2 = 0.44), and even after including BMI in
the model (t (89) = 2.33, P = 0.022, R2 = 0.44). This
model was able to account for 44% of variability in mean
UA levels.
Plasma UA levels were significantly different between
groups with BMI < 25 and BMI ≥ 25 (t96 = −4.91,
P ≤ 0.001). As expected, VAT fat mass was significantly
different between groups with BMI < 25 and BMI ≥ 25
(Mann–Whitney U = 230, P ≤ 0.001 two-tailed). In the
group with BMI < 25, after controlling for age, gender
and eGFR, VAT fat mass was not significantly associated
with UA (t (36) = 1.54, P ≥ 0.05, R2 = 0.28). However, in
the group with BMI ≥ 25, there was a statistically signifi-
cant positive association between plasma UA and
visceral adipose tissue fat mass (t (49) = 2.76, P = 0.008,
R2 = 0.31).
Plasma UA level was significantly different between
groups with VAT fat mass ≤ 300 and VAT fat mass > 300 g











Age (years) 55.98 ± 8.83 56.60 ± 9.40 55.40 ± 8.33 NSa
FPG (mmol/L) 5.11 ± 0.60 5.19 ± 0.70 5.03 ± 0.49 NSb
HbA1c (IFCC) (mmol/mol) 34.60 ± 3.55 34.83 ± 3.86 34.38 ± 3.25 NSb
UA (mmol/L) 0.32 ± 0.07 0.35 ± 0.07 0.28 ± 0.06 P < 0.001b
TG (mmol/L) 1.23 ± 0.62 1.38 ± 0.75 1.09 ± 0.45 NSa
LDL-C (mmol/L) 3.24 ± 0.99 3.32 ± 0.9 3.17 ± 1.05 NSa
HDL–C (mmol/L) 1.65 ± 0.51 1.36 ± 0.31 1.92 ± 0.50 P < 0.001a
TC (mmol/L) 5.51 ± 1.15 5.41 ± 1.08 5.60 ± 1.21 NSa
CRP (mg/L) 1.42 ± 1.30 1.33 ± 1.28 1.51 ± 1.32 NSa
IL-6 (pmol/L) 2.67 ± 1.96 2.57 ± 1.99 2.75 ± 1.94 NSa
TNF-α (pmol/L) 8.13 ± 2.41 8.31 ± 2.48 7.97 ± 2.35 NSa
Estimated GFR (mL/min/1.73 m2) 80.36 ± 9.91 81.34 ± 9.12 79.48 ± 10.58 NSa
BMI (kg/m2) 26.24 ± 4.58 26.31 ± 4.02 26.17 ± 5.11 NSa
Android to gynoid fat ratio 1.13 ± 0.32 1.32 ± 0.30 0.95 ± 0.23 P < 0.001b
VAT fat mass (g) 953.12 ± 798.26 1277.25 ± 870.96 672.63 ± 610 P < 0.001a
SAT fat mass (g) 1314.44 ± 673.77 1009.14 ± 476.72 1601.78 ± 708.85 P < 0.001a
aComparisons made using Mann-Whitney U Test
bComparisons made using the Independent T Test
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(t58.280 = −5.10, P ≤ 0.001). After controlling for age,
gender and eGFR, no significant association was ob-
served between plasma UA and VAT fat mass in the
group with VAT fat mass ≤ 300 g (t (14) = − 1.54,
P ≥ 0.05, R2 = 0.13). However, VAT fat mass was signifi-
cantly associated with plasma UA in the group with VAT
fat mass > 300 g (t (71) = 3.63, P ≤ 0.001, R2 = 0.39).
No association was observed between plasma UA and
SAT fat mass (r (97) = 0.02, P ≥ 0.05).
Associations between plasma UA, plasma TG, TC, LDL-C
and HDL-C
A statistically significant positive association was
observed between plasma UA and plasma TG (rs
(95) = 0.40, P ≤ 0.001). This association remained statis-
tically significant after controlling for age, gender, eGFR
and BMI (t (88) = 2.30, P = 0.024, R2 = 0.47), but no lon-
ger remained significant after adjustment for VAT fat
mass (t (86) = 1.48, P ≥ 0.05, R2 = 0.44).
There was no association found between plasma UA,
TC (r (98) = 0.03, P ≥ 0.05) and LDL-C (r (98) = 0.13,
P ≥ 0.05).
There was a statistically significant negative association
between plasma UA and plasma HDL-C (r (98) = − 0.61,
P ≤ 0.001) (Fig. 3). Since the residuals for the linear regres-
sion model were not normally distributed when gender
was in the equation, the association between plasma UA
and HDL-C was analysed separately for each gender. The
results showed that after controlling for age, eGFR and
BMI, there was a statistically significant negative associ-
ation between plasma UA and plasma HDL-C in males (t
Fig. 1 Associations between plasma uric acid and a Fasting plasma
glucose b Plasma HbA1c
Fig. 2 Associations between plasma uric acid and a BMI b VAT fat
mass. *Data represented as base-10 log-transformed BMI, †data rep-
resented as Square root VAT fat mass
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(41) = −2.46, P = 0.018, R2 = 0.43), but not for females (t
(46) = −1.52, P ≥ 0.05, R2 = 0.25). Also, after controlling
for age, eGFR and VAT fat mass, the association remained
statistically significant in males (t (39) = −2.16, P = 0.037,
R2 = 0.43), but not for females (t (46) = −1.57, P ≥ 0.05,
R2 = 0.29). After controlling for age, eGFR, BMI and VAT
fat mass, no significant association was observed in males
(t (38) = −1.99, P ≥ 0.05, R2 = 0.43) and females (t
(45) = −1.43, P ≥ 0.05, R2 = 0.27).
Associations between plasma UA and plasma
inflammatory markers CRP, TNF- α and IL-6
A statistically significant positive association was
observed between plasma UA and plasma CRP (rs
(98) = 0.23, P = 0.026). Since the linear regression model
did not meet the assumption of normality of residuals,
and transformation was not helpful in solving this issue,
the association between plasma UA and CRP was analysed
separately for each gender. This association remained sta-
tistically significant after adjustment for age and eGFR in
both males (t (41) = 2.55, P = 0.015, R2 = 0.12) and fe-
males (t (45) = 3.16, P = 0.003, R2 = 0.13). It also remained
statistically significant after further adjusting for VAT fat
mass in females (t (44) = 2.47, P ≤ 0.05, R2 = 0.37), but not
for males (t (38) = 2.13, P ≥ 0.05, R2 = 0.05). However, the
association did not remain significant after adjusting for
BMI in the model in either males (t(40) = 0.75, P ≥ 0.05,
R2 = 0.20) or females (t (44) = 1.471, P ≥ 0.05, R2 = 0.46).
After controlling for age, eGFR, BMI and VAT fat mass,
no significant association was observed in males (t
(37) = 0.27, P ≥ 0.05, R2 = 0.11) and females (t (43) = 0.21,
P ≥ 0.05, R2 = 0.48).
No association was observed between plasma UA and
other inflammatory markers tested, plasma TNF-α (r
(97) = 0.12, P ≥ 0.05), and plasma Il-6 (r (96) = −0.02,
P ≥ 0.05).
Discussion
A number of cross-sectional and prospective cohort
studies support an association between plasma/serum
UA and diabetes risk [2–4]. However, as many dia-
betes risk factors also closely correlate with UA [24,
25], it is challenging to make a definite conclusion
about whether UA is actually an independent risk fac-
tor for diabetes. While several studies have shown the
association between UA and visceral adiposity [24, 25,
26], no study has yet considered controlling for vis-
ceral fat mass. Therefore, in order to improve our un-
derstanding of whether UA is an independent risk
factor or an otherwise dependent marker for diabetes,
we investigated the associations between plasma UA
and FPG, HbA1c, lipid profile and inflammatory
markers considering BMI and VAT fat mass contribu-
tion. To the best of our knowledge, this is the first
examination of non-diabetic males and females for
the association between UA and diabetes risk factors
taking in to account DXA-measured VAT fat mass.
Consistent with previous reports [24] we observed that
plasma UA levels were significantly higher in males than
females, most likely due to the effect of estrogen on en-
hancing renal clearance of UA [27]. We also observed a
positive association between plasma UA and FPG and
HbA1c after adjustment for age, gender and eGFR,
consistent with previous observations by others [6, 11,
28, 29]. However, these associations did not remain sig-
nificant after we adjusted for BMI or VAT fat mass.
Similar to our findings, Nan et al. also found the associ-
ation between UA and glucose did not remain significant
after adjustment for BMI [28]. However, in a cross-
sectional study in healthy Korean men the reported
Fig. 3 Associations between plasma uric acid and HDL-C in a males
b Females. *Data represented as base 10-log transformed HDL-C
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positive association between serum UA and glucose
appeared to be independent of BMI [29]. Though, the
potential contribution of VAT fat mass was not assessed
in these studies. Another study, reported that even
though elevated plasma UA was associated with higher
diabetes risk independent of other risk factors such as
obesity, the degree of adiposity (BMI and waist circum-
ference) was responsible for a large part of the associ-
ation between plasma UA and diabetes risk [4]. Similar
to our findings, Wei et al., observed a positive associ-
ation between UA and HbA1c in normoglycemic sub-
jects that did not remain significant after adjustment for
a cluster of confounders such as age, sex, and BMI [6].
In the present study, dual-energy X-ray absorptiometry
(DXA), was used for the measurement of android to
gynoid fat ratio and visceral and subcutaneous adipose
tissue. VAT computed by DXA has been validated using
CT (computed tomography), the gold standard for vis-
ceral fat quantification [30]. It is an inexpensive method
with lower radiation dosage. To the best of our know-
ledge, no study has yet investigated the association be-
tween FPG and DXA measured VAT, and android to
gynoid fat ratio in non-diabetic middle-aged males and
females. Both android fat and gynoid fat measures have
been shown to be closely correlated with traditional fat
measures like waist circumference and hip circumfer-
ence, though they are considered more precise indices of
the association between fat distribution and metabolic
disease [16]. To determine the specific correlates of an-
droid fat components, we investigated the associations
between VAT (visceral adipose tissue) and SAT (subcu-
taneouse adipose tissue) fat mass, FPG and plasma UA.
Furthermore, for the first time, we used the recently sug-
gested VAT fat mass cut-off value of 300 g as a cut-point
for metabolic syndrome risk, in young, healthy and lean
women [31], to compare the UA levels in two groups of
high and low VAT fat mass values.
Consistent with previous studies [15], we observed sig-
nificant associations between FPG, plasma TG and BMI.
Furthermore, our results showed significant associations
between FPG, android to gynoid fat ratio and VAT fat
mass, but not SAT fat mass. This observation is sup-
ported by previous studies in women [16, 31] and adds
further evidence for the value of DXA-measured VAT fat
mass and android to gynoid fat ratio to predict the FPG
in non-diabetic middle-aged males and females.
Importantly the observed positive association between
plasma UA and BMI independent of age, gender and
eGFR, did not remain significant after further adjust-
ment for VAT fat mass. However, the positive association
between plasma UA and VAT fat mass remained signifi-
cant after adjustment for age, gender, eGFR and even
BMI. The absence of any association between plasma
UA and SAT fat mass suggests that visceral fat is a
primary driver in the process leading to high plasma UA
levels. Our results are consistent with that of others
which suggest increased visceral adiposity is a more sen-
sitive predictor of metabolic changes, such as increase in
plasma UA levels than the less nuanced physiological
measure of BMI [26, 32].
Our data has also shown that android to gynoid fat ra-
tio was significantly associated with UA after adjustment
for age, gender, eGFR, BMI, but not VAT fat mass. Simi-
larly, another study reported a positive association be-
tween UA and DXA-measured VAT fat area and android
to gynoid fat ratio in diabetics. Though, the potential
contribution of BMI or VAT fat mass was not assessed
in that study [25].
Much of the literature addressing the association be-
tween plasma UA and glucose has focused on adjust-
ment for BMI, or waist circumference [12, 13, 33].
However, recent application of DXA has allowed us to
investigate this association in more detail for the poten-
tial confounding effects of abdominal and visceral fat de-
position. Based on findings of our and similar studies
[26, 32] it can be suggested that higher visceral fat accu-
mulation, which is also reflected in higher android to
gynoid fat ratio, may have a greater influence on the UA
metabolism than the less specific BMI measure which
includes subcutaneous fat accumulation. While the
mechanisms responsible for this association are not
completely understood, it has been shown that adipose
tissue xanthine oxidoreductase activity can increase UA
production in obese mice [34]. Visceral fat has also been
shown to be associated more closely with overproduc-
tion of UA than subcutaneous fat in obese subjects [32].
VAT may have differential metabolic risks compared to
SAT [35]. It is metabolically active and regulates
numerous adipocytokines which have been associated
with insulin resistance [36]. Insulin resistance or hyper-
insulinemia can increase UA reabsorption from the renal
tubules, reducing urinary UA excretion and thereby in-
creasing circulating plasma UA levels [37]. Furthermore,
increased VAT accumulation causes the over-flow of free
fatty acids to the liver and the overproduction of very
low-density lipoproteins and TG. The increased need for
NADPH during this increase in lipid synthesis acceler-
ates the pentose phosphate pathway which leads to the
de novo purine synthesis, thus increasing the production
of UA [38, 39]. In our study, the VAT fat mass was sig-
nificantly and positively associated with the plasma TG
levels (data not shown), and the plasma TG levels were
positively associated with the plasma UA levels after ad-
justment for possible confounders such as BMI support-
ing the relationship between UA production and TG
synthesis [24]. Consistent with this hypothesis, another
study in normal Japanese men showed that plasma TG
was positively associated with plasma UA [26]. More
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importantly, considering the observed strong associa-
tions between VAT fat mass and FPG and also VAT fat
mass and UA in our study, it can be suggested that the
association between UA and FPG is largely dependent
on VAT fat mass which may have direct causal links to
both increased plasma UA and increased FPG.
We observed no significant association between
plasma UA and TC and LDL-C which was consistent
with the findings of others [40]. Our data showed a
negative association between UA and HDL-C. However,
this association did not remain significant after adjust-
ment for BMI and VAT fat mass. Consistent with our re-
sults, a population-based study showed that after
adjustment for BMI and waist circumference, the associ-
ation between UA and HDL-C is lost [41].
A positive association between plasma UA and CRP
was observed. However, this association did not remain
significant after adjustment for age, eGFR, BMI and
VAT fat mass. Similarly, in another study, the association
between UA and hsCRP (high-sensitivity CRP) did not
remain significant after adjustment for BMI and waist
circumference [42]. The individual inflammatory
markers of IL-6 and TNF-α, were also not significantly
associated with plasma UA as previously reported [43].
Therefore VAT fat mass, rather than UA appears to be a
primary driver of inflammation.
While the conclusions in this study are robust, our study
had several limitations. First, the cross-sectional nature of
the study does not allow us to confirm causality. Also the
relatively small number of subjects (n = 100) may reduce
the sensitivity for identification of relationships with small
effect sizes. Finally, it has been previously reported that
DXA underestimates abdominal adiposity in individuals
with lower abdominal fat, and may overestimate it in indi-
viduals with greater abdominal fat [44, 45]. However, the
accuracy of VAT measures by DXA has since been verified
as accurate by CT in a more recent study [30]. Future
studies overcoming these limitations are required to verify
the consistency of our observations.
Conclusion
This study has demonstrated, for the first time, that the
associations between plasma UA and diabetes risk fac-
tors are largely dependent on VAT fat mass, a specific
measure of fat deposition than BMI. Our findings may
be clinically relevant in terms of primary preventive
strategies for chronic disease especially diabetes which
may necessitate the need to monitor high VAT fat mass
and the consequent high plasma UA as potential prog-
nostic factors.
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